The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2015

Filed:

Oct. 07, 2010
Applicants:

Clifford Charles Shone, Alderbury, GB;

Keith Alan Foster, Salisbury, GB;

John Chaddock, Salisbury, GB;

Philip Marks, Salisbury, GB;

J. Mark Sutton, Salisbury, GB;

Patrick Stancombe, Salisbury, GB;

Jonathan Wayne, Salisbury, GB;

Inventors:

Clifford Charles Shone, Alderbury, GB;

Keith Alan Foster, Salisbury, GB;

John Chaddock, Salisbury, GB;

Philip Marks, Salisbury, GB;

J. Mark Sutton, Salisbury, GB;

Patrick Stancombe, Salisbury, GB;

Jonathan Wayne, Salisbury, GB;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 39/08 (2006.01); A61K 47/48 (2006.01); C07K 14/33 (2006.01); C07K 16/12 (2006.01); C12N 9/52 (2006.01); C12N 15/62 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/08 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 47/48261 (2013.01); A61K 47/4833 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/627 (2013.01); C07K 14/33 (2013.01); C07K 16/1282 (2013.01); C07K 2316/96 (2013.01); C07K 2317/00 (2013.01); C07K 2319/20 (2013.01); C07K 2319/23 (2013.01); C07K 2319/50 (2013.01); C07K 2319/55 (2013.01); C07K 2319/705 (2013.01); C07K 2319/75 (2013.01); C12N 9/52 (2013.01); C12N 15/62 (2013.01); Y10S 530/825 (2013.01);
Abstract

A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide, is possible and the polypeptide can be incorporated into vaccines and toxin assays.


Find Patent Forward Citations

Loading…